IGPH Stock Overview
IGEA Pharma N.V. commercializes health-tech and med-tech products and devices in the Netherlands and rest of Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
IGEA Pharma N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 0.0015 |
| 52 Week High | CHF 0.05 |
| 52 Week Low | CHF 0.001 |
| Beta | -1.31 |
| 11 Month Change | 200.00% |
| 3 Month Change | -25.00% |
| 1 Year Change | -96.88% |
| 33 Year Change | -99.72% |
| 5 Year Change | -99.94% |
| Change since IPO | -99.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| IGPH | CH Medical Equipment | CH Market | |
|---|---|---|---|
| 7D | 200.0% | -3.3% | -1.4% |
| 1Y | -96.9% | 10.0% | 5.2% |
Return vs Industry: IGPH underperformed the Swiss Medical Equipment industry which returned 19.8% over the past year.
Return vs Market: IGPH underperformed the Swiss Market which returned 3.3% over the past year.
Price Volatility
| IGPH volatility | |
|---|---|
| IGPH Average Weekly Movement | 123.2% |
| Medical Equipment Industry Average Movement | 3.9% |
| Market Average Movement | 3.4% |
| 10% most volatile stocks in CH Market | 6.6% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: IGPH's share price has been volatile over the past 3 months.
Volatility Over Time: IGPH's weekly volatility has increased from 75% to 123% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 1 | Pierpaolo Cerani | www.igeapharma.nl |
IGEA Pharma N.V. commercializes health-tech and med-tech products and devices in the Netherlands and rest of Europe. It offers Alz1, an at-home lab test kit to measure non-bound copper in the blood; functional foods; and dietary supplement products to reduce blood heavy metals content under the Alz1 Tab brand. The company also provides dry aerosol generators for air and inanimate environmental surfaces sanitization, as well as air sterilization and purification devices.
IGEA Pharma N.V. Fundamentals Summary
| IGPH fundamental statistics | |
|---|---|
| Market cap | CHF 505.55k |
| Earnings (TTM) | -CHF 10.92m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs IGPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IGPH income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €11.56m |
| Earnings | -€11.56m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.034 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -47.1% |
How did IGPH perform over the long term?
See historical performance and comparison